Silence Therapeutics PLC

Receive alerts
Market Cap:
£176.49 m
52 weeks high
52 weeks low

Viewing results 1-25 of 202

Retail & consumer

Proactive news snapshot: Hurricane Energy, Arc Minerals, Alba Mineral Resources...

A glance at some of the highlights from the Proactive newswire today ...

2 days, 22 hours ago

Silence Therapeutics well capitalised to carry out "strategic objectives"

The company had £36mln of cash as at August 31, putting it in a strong financial position ...

3 days, 6 hours ago

Silence Therapeutics looks to unlock further potential after 'transformational' year

The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use...

on 14/8/19

Silence Therapeutics appoints industry veteran to oversee manufacturing

"It is exciting to be involved in the development of products which have the potential to positively impact the lives of patients with serious diseases," said Wittendorff...

on 5/8/19

Silence Therapeutics appoints independent director from US partner company

He is Dr Steven Romano, the chief scientific officer at Mallinckrodt Pharmaceuticals, who has also held senior roles Pfizer and Eli Lilly...

on 29/7/19

Silence Therapeutics agrees major collaboration with US firm Mallinckrodt

Silence said the collaboration has the potential to bring in up to US$2bn in clinical, regulatory and commercial payments for its assets ...

on 18/7/19

Silence Therapeutics given access to genetic database in its bid to find new breakthrough treatments

Genomics England has whole sequencing data on 100,000 genomes...

on 28/5/19

Silence Therapeutics says Iain Ross to return as its chairman and non-executive director with immediate effect

Ross was Silence's chairman from 2005 to 2010 and is currently is non-executive chairman at Kazia Therapeutics Limited, e-Therapeutics PLC and Redx Pharma PLC...

on 25/4/19

Silence Therapeutics confirms Dr Rob Quinn as chief financial officer

"I'm very pleased that Rob will serve as full-time chief financial officer and on behalf of the board I would like to formally welcome him to this role," said David Horn Solomon, Silence's CEO...

on 18/4/19

Silence Therapeutics makes key new hire

Giles Campion has been appointed head of research and development and chief medical officer...

on 16/4/19

Silence Therapeutics makes clinical trial application for lead drug

Chief executive, Dr David Horn Solomon, said the submission was a “very positive step forward” as it continued preparations for its return to the clinic...

on 27/3/19

Silence Therapeutics gearing up for “exciting” year

Silence is to kick off its first-ever in-human clinical trial later this year when it puts its SLN124 β-Thalassemia treatment through its paces ...

on 11/3/19

Silence Therapeutics higher as lead medicine candidate granted orphan drug status

Orphan drug status gives drugmakers certain benefits to encourage them to develop treatments for rare diseases which might otherwise lack sufficient profit motive...

on 15/1/19

Silence Therapeutics finance chief departs

Silence’s group head of financial planning and analysis, Rob Quinn, will take on the outgoing David Ellam’s responsibilities for the time being whilst a permanent successor is found...

on 9/1/19

Silence Therapeutics adds new siRNA asset to pre-clinical pipeline for potential treatment of cardiovascular disease

The firm, a leader in the discovery, development and delivery of novel RNA therapeutics, said the proprietary product candidate, SLN360, silences apolipoprotein, a component of lipoprotein(a) (LP(a)...

on 19/12/18

Silence Therapeutics reaches settlement and licence agreement with Alnylam, ending patent battle

Alnylam will license patents from Silence and will pay the UK-listed group a tiered royalty on net sales of the US biotech group’s ONPATTRO drug in the EU only, ranging from 0.33%to 1.0% through 2023...

on 10/12/18

Silence Therapeutics gets one over on Alnylam in ongoing patent battle

The US Patent Trial and Appeal Board found that Alnylam didn’t have enough evidence to prove a patent recently awarded to Silence should be invalidated ...

on 11/10/18

Silence Therapeutics's Alnylam wrangle takes a new turn

The two are at loggerheads over the patented technology at the heart of the US group's first commercial drug...

on 10/10/18

Silence Therapeutics to kick off first-in-human clinical trial next year

The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019...

on 11/9/18

Silence Therapeutics chair Annalisa Jenkins steps down

Silence Therapeutics said non-executive director Andy Richards has been appointed interim chair ...

on 20/8/18